

SHORT REPORT

Open Access

Intranasal vaccination with extracellular serine proteases of *Leishmania amazonensis* confers protective immunity to BALB/c mice against infection

Herbert Leonel de Matos Guedes^{1,5*}, Beatriz Lilian da Silva Costa¹, Suzana Passos Chaves¹, Daniel Cláudio de Oliveira Gomes³, Joshua Daniel Nosanchuk⁴, Salvatore Giovanni De Simone² and Bartira Rossi-Bergmann^{1*}

Abstract

Background: Previously, we demonstrated that unlike subcutaneous or intramuscular vaccination, intranasal vaccination of BALB/c mice with whole *Leishmania amazonensis* antigens leads to protection against cutaneous leishmaniasis. Here, the role of parasite serine proteases in the protective immunity was investigated.

Findings: Serine Proteases were partially purified from both soluble (LaSP-Sol) and extracellular (LaSP-Ex) *Leishmania amazonensis* promastigote extracts by aprotinin-agarose chromatography. BALB/c mice were intranasally immunized with LaSP-Sol and LaSP-Ex prior to infection with *L. amazonensis*. LaSP-Ex but not LaSP-Sol vaccination led to significantly smaller lesions and parasite burdens as compared with non-vaccinated controls. Protection was accompanied by systemic Th1 polarization with increased IFN- γ and decreased IL-4 and IL-10 splenic production. Likewise, increased production of IFN- γ , IL-12 and IL-4 concomitant with decreased TGF- β and TNF- α was locally observed in the infected footpad.

Conclusion: This study indicates that extracellular serine proteases of *L. amazonensis* are strong candidates for a more defined intranasal vaccine against cutaneous leishmaniasis.

Keywords: *Leishmania amazonensis*, Murine cutaneous leishmaniasis, Mucosal vaccine, Intranasal route, Extracellular serine proteases

Background

Leishmaniasis is a complex of diseases caused by different species of *Leishmania* protozoans affecting over 11 million people worldwide, with an estimated 1.3 million new cases a year. Clinical manifestations vary from a localized cutaneous lesion to lethal visceral infection [1]. Although protective immunity can be acquired following natural infection, three vaccines are currently on the

market against canine visceral leishmaniasis [2], and a multisubunit recombinant *Leishmania* vaccine formulated with the MPL-SE adjuvant have progressed to phase-II clinical trials against cutaneous and visceral leishmaniasis [3,4], no vaccine has been considered safe and/or effective enough for human approval [5]. One of the most extensively studied human vaccines is Leishvacin[®], comprised of whole-killed promastigotes of *L. amazonensis*, which have been shown to convert the Montenegro skin test and induce IFN- γ responses in human volunteers, but its efficacy was not confirmed after a controlled phase III clinical trial in Colombia [6], in line with studies in mice and in monkeys showing that adjuvant-free *L. amazonensis* antigens is counter-protective [7,8].

* Correspondence: herbert@biof.ufrj.br; bartira@biof.ufrj.br

¹Laboratório de Imunofarmacologia, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, 21941-902 Rio de Janeiro, RJ, Brazil

⁵Núcleo Multidisciplinar de Pesquisa UFRJ – Xerém em Biologia (NUMPEX-BIO), Polo Avançado de Xerém – Universidade Federal do Rio de Janeiro, 25245-390 Duque de Caxias, RJ, Brazil

Full list of author information is available at the end of the article

In common, all the vaccines above were given by subcutaneous or intramuscular (i.m.) routes. Mucosal vaccination is an effective way to induce active immunity against infective agents entering the body through the mucosa, and also an interesting strategy to induce local and peripheral tolerance to otherwise disease-promoting antigens such as allergens in a non-invasive fashion [9]. In this context, the nasal mucosa may work in a way similar to the oral route, but ease of administration, lower antigen dose and lower degradation of the antigen are the main positive factors of its use in relation to the oral route [10].

We previously showed that contrary to the i.m. route, both oral and intranasal (i.n.) vaccination of mice with whole *L. amazonensis* promastigote antigens (LaAg) led to protection against cutaneous leishmaniasis [7,10,11]. Since LaAg is a complex antigen, we sought to identify active components for a more defined vaccine. Various serine proteases (SPs) have been demonstrated in *Leishmania* [12-14]. The observation that neutralization of SPs and to a lesser extent cysteine proteases with specific inhibitors rendered LaAg protective via i.m. vaccination, and that i.m. vaccination with partially purified soluble serine proteases enhanced mouse susceptibility to *L. amazonensis* infection [15], we proposed here to evaluate the protectiveness of SPs from intracellular and extracellular parasite extracts against *L. amazonensis* infection using the i.n. route of administration.

Findings

Methods

Animals

BALB/c mice were originally obtained from Jackson Laboratory (Bar Harbor, Maine), and bred and maintained at our facilities at Universidade Federal do Rio de Janeiro using sterilized bedding, filtered water, and commercial pelleted food, mice were maintained under a controlled temperature. Female mice were used at 6–8 weeks of age in all experiments. Experiments were approved under the protocol # CAUAP180 by the Committee for Ethical Use of Experimental Animals at CCS/Federal University of Rio de Janeiro (Brazil).

Parasites

For antigen preparation, *Leishmania amazonensis* (IFLA/BR/67/PH8) routinely isolated from mouse lesions were transformed and maintained as promastigotes at 26°C in M199 medium containing 10% heat-inactivated fetal bovine serum (HIFCS, GIBCO Laboratories, Grand Island, NY). For infection, *L. amazonensis* (MHOM/BR/75/Josefa) transfected with green fluorescent protein (*L. amazonensis*-GFP) were routinely isolated from mouse lesions and maintained as promastigotes at 26°C in M199 medium containing 10% heat-inactivated fetal

bovine serum (HIFCS). Parasites were periodically selected for bright fluorescence using 1 mg/mL of geneticin (Sigma) [16].

LaAg

L. amazonensis promastigote antigens (LaAg) were prepared as previously described [15]. Briefly, stationary-growth phase promastigotes were washed three times in phosphate buffered saline (PBS) and subjected to three cycles of freezing and thawing. LaAg was lyophilized, stored at -20°C and reconstituted with PBS immediately prior to use.

Serine protease purification

The soluble serine protease fraction (LaSP-Sol) and extracellular serine protease fraction (LaSP-Ex) were purified as previously described [12-14]. The soluble serine protease fraction (LaSP-Sol) was purified from soluble extract of promastigotes [12] and the extracellular serine protease fraction (LaSP-Ex) was purified from parasite culture supernatants [13]. For that, 4×10^{11} promastigotes (2×10^7 /mL) were cultured in 2 L of Brain Heart Infusion (BHI) medium containing 10% HIFCS to the stationary-phase of growth. Promastigotes were washed three times in phosphate buffered saline (PBS) and subjected to three cycles of freezing and thawing in Tris-HCl buffer, pH 7.5, containing 5 mM CaCl₂ and the cell lysate was centrifugated ($100,000 \times g$ for 30 min at 4°C) to remove the non-soluble aggregates, thus producing a soluble fraction. The culture supernatants (2 L) were precipitated overnight with 45% (NH₄)₂SO₄ and centrifuged ($10,000 \times g$ for 30 min at 25°C). The pellet was suspended in 100 mL of 10 mM Tris-HCl buffer, pH 7.5, containing 5 mM CaCl₂, dialyzed four times against 2 L of the same buffer, and centrifuged ($20,000 \times g$ for 30 min at 4°C) producing extracellular fraction.

The soluble fraction or extracellular fraction were loaded onto a pre-equilibrated (10 mM Tris-HCl buffer, pH 7.5, containing 5 mM CaCl₂) aprotinin-agarose affinity column (2.5 ml; Sigma-Aldrich). After washing with 20 bed volumes, the material was eluted with 10 mM Tris-HCl buffer, pH 7.5, containing 1.5 M NaCl. One mL fractions were collected on ice and the effluents absorption at 280 nm was monitored to detect protein peak. Protein fractions were then pooled (LaSP-Sol or LaSP-Ex), dialyzed against phosphate buffered saline (PBS), and the protein concentration was quantified by the Lowry method.

Immunization, infection challenge and evaluation of disease progression

Animals received 20 µg of LaSP-Sol or LaSP-EX in 20 µL of PBS by instillation of 10 µL in each nostril using a micropipette adapted with a polystyrene microtip. A

booster dose was given 7 days later [10]. Controls received PBS alone. Seven days after the vaccine boost, animals were subcutaneously injected in the hind footpad with 2×10^5 stationary-phase *L. amazonensis*-GFP promastigotes (7 days of culture). Alternatively, for a lower virulence infection that allowed non-vaccinated controls not to ulcerate (approximately 3 mm of thickness) before 100 days of infection, animals were infected with 2×10^5 promastigotes at the beginning of stationary-phase of growth (4 days of culture). Lesion sizes were periodically measured with a dial caliper and expressed as the difference between the thicknesses of infected and contralateral non-infected footpads. For parasite load determination, the fluorescence intensity of the tissue homogenates were determined as described previously [11]. Briefly, at the end of the experiments each infected foot was skinned and individually homogenized in 1 mL of PBS using a tissue grinder. Tissue debris was removed by gravity sedimentation for 5 min, and then 2-fold serially diluted in PBS in triplicates for fluorescence intensity measurements using a plate-reader fluorimeter (FLX 8000, Bio-Tek) at 435 nm excitation and 538 nm emission.

Cytokines

For splenic cells, spleens were isolated at 7 days after infection, and single-cell suspensions were adjusted to 4×10^6 per ml in Dulbecco's minimal essential medium containing 10% HIFCS, 20 mM HEPES, 50 μ M 2-mercaptoethanol, 2 mM L-glutamine, 50 U/ml penicillin, 50 μ g/ml streptomycin sulfate (Sigma-Aldrich) and 1 mL samples were plated in 24-well tissue culture. Cells were cultured for 48 h in the presence of 5 μ g/mL of LaAg, when they were centrifuged and the supernatants collected. For lymph node cells, at 7 days after infection the popliteal lymph nodes were isolated and the cells were cultured as above using 50 μ g/mL of LaSP-Sol or LaSP-Ex. For *in situ* production, infected footpads were isolated, skinned, weighed, teased and individually homogenized in 1 mL of PBS using a glass tissue homogenizer. The footpad homogenates were centrifuged (10 min, $20\,000 \times g$ at 4°C) and the supernatants collected. For cytokine quantification, supernatants prepared as above were assayed for TGF- β , IFN- γ , IL-10, IL-4, IL-12 and TNF- α by ELISA following the manufacturer's instructions (R&D Systems, Minneapolis, USA). For TGF- β , the supernatants were pre-heated to 80°C for 5 min prior to the assay [7].

Statistical analysis

Each experiment was performed three times and similar patterns of results were achieved. Due to expected variations among lesion growth rates in PBS controls, the result is representative of one experiment. The differences between vaccinated and non-vaccinated groups were

statistically determined by Student *t*-test or Anova using the GraphPad InStat software, and were considered significant when $p \leq 0.05$.

Results

Intranasal vaccination with LaSP-Ex but not LaSP-Sol protects mice against infection

The efficacy of i.n. vaccination with LaSP-Ex and LaSP-Sol were evaluated in *L. amazonensis*-challenged mice seven days after a booster. Vaccination with LaSP-Sol did not significantly alter the course of infection as compared with controls (Figure 1A). On day 70 of infection, when there was a slight lesion outgrowth, the parasite loads were higher than controls (Figure 1B), indicating that i.n. LaSP-Sol led to increased susceptibility to infection. Opposite to LaSP-Sol, LaSP-Ex effectively controlled lesion growth (Figure 1A) and parasite Load (Figure 1B). In the low virulent infection, we followed infections until day 125. We observed a high level of protection by delay of growth curve and control of the lesion size (Figure 2A). The parasite burden in the footpads was significantly lower than controls (Figure 2B), confirming the lesion control finding.

Intranasal LaSP-Ex induces Th1 systemic polarization

We evaluated the cytokine production by spleen cells of LaSP-Ex-vaccinated animals at an early stage of infection (7 days after challenge). Upon antigen (LaAg)-stimulation, cells from vaccinated mice produced increased IFN- γ (Figure 3A) and decreased levels of IL-4 and IL-10 (Figure 3B and C), whereas TGF- β was not modulated (Figure 3D). The cytokine levels from LaSP-Sol-vaccinated mice were similar to non-vaccinated PBS controls (not shown), suggesting that the failure of this group may be related to lack of a proper systemic cytokine modulation. At the same time, these findings suggest that protective immunity of LaSP-Ex was associated with a Th1-skewed cytokine production.

Intranasal LaSP-Ex protection is accompanied by mixed *in situ* cytokine responses

To investigate the mechanism of protection of i.n. LaSP-Ex, the *ex vivo* production of key pro-inflammatory (IFN- γ , IL-12 and TNF- α) and anti-inflammatory (IL-4, IL-10 and TGF- β) cytokines were evaluated in the footpads at the end of the experiments. Figure 4 shows a higher production of IFN- γ , IL-4 and IL-12 (Figure 4A, D and E) concomitant with reduced TGF- β and TNF- α (Figure 4C and F) and unaltered IL-10 (Figure 4B) in relation to non-vaccinated controls, indicating a mixed pro- and anti-inflammatory local cytokine response.

Discussion

Few vaccines that have been administered by the mucosal route are able to stimulate effective cell-mediated




Figure 1 Efficacy of i.n. LaSP-Sol and LaSP-Ex against *L. amazonensis* infection. BALB/c mice received 20 µg of LaSP-Sol or LaSP-Ex by the i.n. route on days -14 and -7 of infection. Non-vaccinated controls received PBS alone. On day 0, animals were infected with 2×10^5 stationary-phase promastigotes of *L. amazonensis*-GFP (7 days of culture). **A)** Lesion sizes were measured at the indicated days and are expressed as the difference of thickness between non-infected and infected footpads. **B)** The parasite loads were measured on day 70 of infection and are expressed as fluorescence units (FU). The data displayed are representative of three independent experiments producing the same result profile. Means \pm SD (n = 5). *p \leq 0.05 and #p \leq 0.01 in comparison to PBS controls.

immune responses, the exceptions being invasive bacterial vaccines [17]. Defined leishmanial antigens such as recombinant LACK [10,18] and Leish-111f [19] were evaluated as vaccines by intranasal route against *Leishmania* infection. Recombinant LACK [18] and Leish-111f [19] only induced protection by intranasal route when associated with cholera toxin as adjuvant. However, cholera toxin is not approved for human use as a mucosal adjuvant [20].

In this work, we evaluated the protectiveness of intranasal vaccination using two new leishmanial serine protease fractions, LaSP-Sol and LaSP-Ex, without any adjuvant against *L. amazonensis* infection. In previous studies, we showed that those two protease fractions display different protein contents [12,13]. Subsequently we showed that intramuscular vaccination with LaSP-Sol leads to enhanced susceptibility to infection, in a manner associated with its capacity to stimulate IL-10 and TGF- β production by immune cells from 7-day infected mice [15]. In the present work, using a similar *in vitro* model, we observed that contrary to LaSP-Sol, LaSP-Ex does not stimulate the production of TGF- β , and actually

inhibits the spontaneous production of IL-10 (Additional file 1: Figure S1). The observed differential antigenicity between these two SP fractions prompted their comparison as mucosal vaccines. Interestingly, LaSP-Sol is comparable to LaAg by i.m. immunization [7,15], but not for i.n. immunization (Figure 1). On the other hand, i.n. LaSP-Ex vaccination promoted resistance to *L. amazonensis* challenge infection (Figures 1 and 2), similar to i.n. LaAg vaccination [10]. The ability of adjuvant-free LaSP-Ex to induce protection is very encouraging, as this is a more defined antigen fraction.

Immunity against *Leishmania* parasites depends largely on activation of cell-mediated responses, and gamma interferon and dendritic cell-derived IL-12 has been shown to play a crucial role in this process [21]. Whereas in *L. major* murine infection, IFN- γ production is more critical at the beginning of infection [22], in *L. amazonensis* infection IFN- γ requirement seems particularly important in the later stages [23]. Here, we have shown the increased production of IFN- γ (Figure 3A) and decreased production of IL-4 and IL-10 (Figure 3B and C)




Figure 2 Protection duration of i.n. LaSP-Ex upon a less virulent infection. BALB/c mice were vaccinated with LaSP-Ex and seven days after the booster animals were challenged with 2×10^5 at the beginning of stationary-phase *L. amazonensis*-GFP (4 days of culture) and monitored as described for Figure 1. **A)** Lesion sizes. **B)** Parasite loads were measured on day 125 of infection. Means \pm SD (n = 5). *p \leq 0.05 and #p \leq 0.01 relative to PBS controls. The data displayed is representative of two independent experiments.




Figure 3 LaSP-EX induces Th1 systemic polarization. Mice were vaccinated and infected as described for Figure 2. At day 7 of infection, their spleen cells were re-stimulated *in vitro* with LaAg (5 μ g/mL), and after 48 hours of culture the levels of IFN- γ (A), IL-4 (B), IL-10 (C) and TGF- β (D) were measured in the supernatants. The data displayed is representative of three independent experiments. Means \pm SD (n = 5). *p \leq 0.05 in relation to PBS.

in spleen cells after seven days of infection that indicates the systemic Th1 polarization induced by LaSP-Ex intranasal vaccination. LaSP-Ex also led to increased peripheral IFN- γ (Figure 4A) in the site of infection as compared to non-vaccinated controls, and this is probably the result of

increased IL-12 (Figure 4E), which is required not only to initiate but also to maintain Th1 cell responses and resistance to *L. major* [24].

Conversely, macrophage deactivating cytokine TGF- β has been associated with disease [7,25,26]. Also, *i.n.*




Figure 4 In situ cytokine profile. Mice were *i.n.* vaccinated with LaSP-Ex and infected with *L. amazonensis*-GFP as described for Figure 2. On day 125 of infection, the levels of IFN- γ (A), IL-10 (B), TGF- β (C), IL-4 (D), IL-12 (E) and TNF- α (F) were measured in the lesion homogenates, and expressed as ng per g of footpad. The data displayed is representative of three independent experiments. Means \pm SD (n = 5). *p \leq 0.05 and #p \leq 0.01 in comparison to PBS controls.

LaSP-Ex vaccination led to a decreased TGF- β production (Figure 4C) in the infected footpads. This is in line with our previous studies showing the reversal of TGF- β production and decreased susceptibility of BALB/c mice given i.m. LaAg devoid of SP activity [15]. The decrease of TNF- α (Figure 4F) could be related to the smaller lesion observed in the vaccinated group, as it has been demonstrated in humans that larger lesions are associated with increase of TNF- α [27]. IL-4 is required for an optimal Th1 response against *L. major*, because of the increase in the production of IL-12 by dendritic cells [28]. The increase of IL-4 (Figure 4D) in the footpad of the vaccinated group suggests the participation of this cytokine in the lesion resolution. Overall, the cytokine balance indicates that even at this late stage of infection (day 125) it tends to be a pro-inflammatory local response.

LaSP-Ex is an exogenous purified antigen from *L. amazonensis* culture. Exogenous antigens from *Leishmania major* culture (SEAg) have been evaluated as vaccine candidates against *L. major*, *L. donovani* and *L. braziliensis* infections in BALB/c mice [29,30]. The immunization with adjuvant-free SEAg by parenteral route induced protection against *L. major* and *L. donovani*, but not against *L. braziliensis*. Two components of SEAg, GP63 and nucleoside hydrolase, induced protection against *L. major* infection [29-31]. The identity of serine proteases in LaSP-Ex remains unknown. We cloned oligopeptidase B (OPB) [32] and oligopeptidase B2 (OPB2) [33] from *Leishmania amazonensis* and we predicted the molecular weight for OPB and OPB2 as 83.49 KDa and 103.92 KDa, respectively. We found two protein bands with similar molecular mass in the extracellular serine proteases fraction of *L. braziliensis* [14], suggesting the presence of OPB and OPB2 in the extracellular serine proteases fraction. Oligopeptidase B is an important virulence factor for trypanosomatids [34,35]. Studies evaluating the components of LaSP-Ex and immunogenicity of recombinant OPB and OPB2 are under way and may help clarify their participation in the protective effect of LaSP-Ex. The evaluation of proteases as antigens for immunization is very important to development of new vaccines against infectious diseases [34,36].

Conclusion

We have previously demonstrated the feasibility of both oral and intranasal (i.n.) vaccination with particulated leishmanial antigens (LaAg) in protecting BALB/c mice against *L. amazonensis* [10,11] and intranasal DNA encoding LACK vaccination protecting BALB/c mice against *L. amazonensis* [11]. In this manuscript, we demonstrate that a more defined antigen, extracellular serine proteases of *L. amazonensis*, is protective via an intranasal route encouraging further work on this second-generation vaccine.

Additional file

Additional file 1: Figure S1. In vitro cytokine production by immune cells stimulated with LaSP-Sol and LaSP-Ex. Lesion-draining lymph node cells were isolated from 7-day infected mice and re-stimulated *in vitro* with 50 μ g/mL of soluble serine proteases of LaAg (LaSP-Sol) or extracellular serine proteases fraction (LaSP-Ex). After 48 h, the levels of IL-10 (A), TGF- β (B) and IFN- γ (C) were measured in the cell supernatants. Means \pm SD (n = 5). *p \leq 0.05 and #p \leq 0.01 in relation to unstimulated controls (medium).

Abbreviations

i.n.: Intranasal; i.m.: Intramuscular; LaSP-Sol: Soluble Serine proteases from *Leishmania amazonensis* promastigotes; LaSP-Ex: Extracellular serine proteases from *Leishmania amazonensis* promastigotes supernatant of culture; SP: Serine proteases.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

Designed experiments and idea: HLMG and BR-B. Performed the animal experiments: HLMG, BLCS, SPC and DCOG. Protein purifications: HLMG and SGS. Cytokines in situ: HLMG and JDN. Discussion of the results: HLMG, DCOG, JDN, SGS and BR-B. Manuscript preparation: HLMG, BLCS, SPC, DCOG, JDN, SGS and BR-B. All authors read and approved the final version of the manuscript.

Acknowledgments

This work was financially supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro, Brazil (FAPERJ). HLMG was also partially supported by an Interhemispheric Research Training Grant in Infectious Diseases, Fogarty International Center (NIH D43-TW007129). We thank Camila A. B. Falcão for her help with *Leishmania amazonensis*-GFP maintenance.

Author details

¹Laboratório de Imunofarmacologia, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, 21941-902 Rio de Janeiro, RJ, Brazil. ²FIOCRUZ-Oswaldo Cruz Foundation. Center for Technological Development in Health (CDTS)/National Institute of Science and Technology of Innovation on Diseases of Neglected Populations, 21045-900 Rio de Janeiro, RJ, Brazil. ³Laboratório de Imunologia Celular e Molecular, Núcleo de Doenças Infeciosas, Universidade Federal do Espírito Santo, 29040-091 Vitória, ES, Brazil. ⁴Departments of Medicine and Microbiology and Immunology, Albert Einstein College of Medicine, Yeshiva University, 10461 Bronx, NY, USA. ⁵Núcleo Multidisciplinar de Pesquisa UFRJ – Xerém em Biologia (NUMPEX-BIO), Polo Avançado de Xerém – Universidade Federal do Rio de Janeiro, 25245-390 Duque de Caxias, RJ, Brazil.

Received: 17 March 2014 Accepted: 1 September 2014

Published: 19 September 2014

References

1. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M, WHO Leishmaniasis Control Team: **Leishmaniasis worldwide and global estimates of its incidence.** *PLoS ONE* 2012, **7**(5):e35671.
2. Otranto D, Dantas-Torres F: **The prevention of canine leishmaniasis and its impact on public health.** *Trends Parasitol* 2013, **29**(7):339–345.
3. Kumar R, Engwerda C: **Vaccines to prevent leishmaniasis.** *Clinical & Translational Immunology* 2014, **3**:e13.
4. Chakravarty J, Kumar S, Trivedi S, Rai VK, Singh A, Ashman JA, Laughlin EM, Coler RN, Kahn SJ, Beckmann AM, Cowgill KD, Reed SG, Sundar S, Piazza FM: **A clinical trial to evaluate the safety and immunogenicity of The Leish-Fl1 + MPL-SE vaccine for use in the prevention of visceral Leishmaniasis.** *Vaccine* 2011, **29**(19):3531–3537.
5. Alvar J, Croft SL, Kaye P, Khamesipour A, Sundar S, Reed SG: **Case study for a vaccine against leishmaniasis.** *Vaccine* 2013, **18**(31 Suppl 2):B244–B249.
6. Velez ID, Gilchrist K, Arbelaez MP, Rojas CA, Puerta JA, Antunes CM, Zicker F, Modabber F: **Failure of a killed Leishmania amazonensis vaccine against**

- American cutaneous leishmaniasis in Colombia. *Trans R Soc Trop Med Hyg* 2005, **99**:593–598.
7. Pinheiro RO, Pinto EF, Lopes JRB, Guedes HLM, Fentanes RF, Rossi-Bergmann B: **TGF- β -associated enhanced susceptibility to leishmaniasis following intramuscular vaccination of mice with *Leishmania amazonensis* antigens.** *Microbes Infect* 2005, **7**(13):1317–1323.
 8. Kenney RT, Sacks DL, Sypek JP, Vilela L, Gam AA, Evans-Davis K: **Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis.** *J Immunol* 1999, **15**(163(8)):4481–4488.
 9. Neutra RM, Kozlowski AP: **Mucosal vaccines: the promise and the challenge.** *Nat Rev Immunol* 2006, **6**(2):148–158.
 10. Pinto EF, Pinheiro RO, Rayol A, Larraga V, Rossi-Bergmann B: **Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK.** *Infect Immun* 2004, **72**(8):4521–4527.
 11. Pinto EF, De Mello CM, Rossi-Bergmann B: **Interferon-gamma-inducing oral vaccination with *Leishmania amazonensis* antigens protects BALB/c and C57BL/6 mice against cutaneous leishmaniasis.** *Vaccine* 2003, **21**(25–26):3534–3541.
 12. Silva-Lopez RE, De-Simone SG: ***Leishmania (Leishmania) amazonensis*: purification and characterization of a promastigote serine protease.** *Exp Parasitol* 2004, **107**(3–4):73–182.
 13. Silva-Lopez RE, Coelho MGP, De-Simone SG: **Characterization of an extracellular serine protease of *Leishmania (Leishmania) amazonensis*.** *Parasitology* 2005, **131**(Pt 1):85–96.
 14. Guedes HLM, Rezende-Neto JM, Abreu MF, de Salles CMC, De Simone SG: **Identification of serine proteases from *Leishmania braziliensis*.** *Z Naturforsch* 2007, **C62**(5–6):373–381.
 15. de Matos Guedes HL, Pinheiro RO, Chaves SP, De-Simone SG, Rossi-Bergmann B: **Serine proteases of *Leishmania amazonensis* as immunomodulatory and disease-aggravating components of the crude LaAg vaccine.** *Vaccine* 2010, **28**(33):5491–5496.
 16. Rossi-Bergmann B, Lenglet A, Bezerra-Santos CR, Costa-Pinto D, Traub-Czeko YM: **Use of fluorescent *Leishmania* for faster quantitation of parasite growth in vitro and in vivo.** *Mem I Oswaldo Cruz* 1999, **94**:74.
 17. Amuguni H, Tzipori S: ***Bacillus subtilis*: a temperature resistant and needle free delivery system of immunogens.** *Hum Vaccin Immunother* 2012, **8**(7):979–986. Review.
 18. McSorley SJ, Rask C, Pichot R, Julia V, Czerkinsky C, Glaichenhaus N: **Selective tolerization of Th1-like cells after nasal administration of a cholera toxoid-LACK conjugate.** *Eur J Immunol* 1998, **28**(2):424–432.
 19. Sakai S, Takashima Y, Matsumoto Y, Reed SG, Hayashi Y, Matsumoto Y: **Intranasal immunization with Leish-111f induces IFN-gamma production and protects mice from *Leishmania major* infection.** *Vaccine* 2010, **28**(10):2207–2213.
 20. Thompson AL, Staats HF: **Cytokines: the future of intranasal vaccine adjuvants.** *Clin Dev Immunol* 2011, **2011**:289597.
 21. Soong L, Henard CA, Melby PC: **Immunopathogenesis of non-healing American cutaneous leishmaniasis and progressive visceral leishmaniasis.** *Semin Immunopathol* 2012, **34**(6):735–751.
 22. Scott P: **Immunologic memory in cutaneous leishmaniasis.** *Cell Microbiol* 2005, **7**:1707–1713.
 23. Pinheiro RO, Rossi-Bergmann B: **Interferon-gamma is required for the late but not early control of *Leishmania amazonensis* infection in C57BL/6 mice.** *Mem Inst Oswaldo Cruz* 2007, **102**:79–82.
 24. Park AY, Hondowicz B, Kopf M, Scott P: **The role of IL-12 in maintaining resistance to *Leishmania major*.** *J Immunol* 2002, **168**(11):5771–5777.
 25. Barral A, Barral-Netto M, Yong EC, Brownell CE, Twardzik DR, Reed SG: **Transforming growth factor beta as a virulence mechanism for *Leishmania braziliensis*.** *Proc Natl Acad Sci U S A* 1983, **15**(90(8)):3442–3446.
 26. Padigel UM, Farrell JP: **Control of infection with *Leishmania major* in susceptible BALB/c mice lacking the common gamma-chain for FcR is associated with reduced production of IL-10 and TGF-beta by parasitized cells.** *J Immunol* 2005, **15**(174(10)):6340–6345.
 27. Oliveira F, Bafica A, Rosato AB, Favali CB, Costa JM, Cafe V, Barral-Netto M, Barral A: **Lesion size correlates with *Leishmania* antigen-stimulated TNF-levels in human cutaneous leishmaniasis.** *Am J Trop Med Hyg* 2011, **85**(1):70–73.
 28. Hurdal R, Nieuwenhuizen NE, Revaz-Breton M, Smith L, Hoving JC, Parihar SP, Reizis B, Brombacher F: **Deletion of IL-4 receptor alpha on dendritic cells renders BALB/c mice hypersusceptible to *Leishmania major* infection.** *PLoS Pathog* 2013, **9**(10):e1003699.
 29. Tonui WK, Mejia JS, Hochberg L, Mbow ML, Ryan JR, Chan AS, Martin SK, Titus RG: **Immunization with *Leishmania major* exogenous antigens protects susceptible BALB/c mice against challenge infection with *L. major*.** *Infect Immun* 2004, **72**(10):5654–5661.
 30. Tonui WK, Titus RG: **Cross-protection against *Leishmania donovani* but not *Leishmania braziliensis* caused by vaccination with *Leishmania major* soluble promastigote exogenous antigens in BALB/c mice.** *Am J Trop Med Hyg* 2007, **76**(3):579–584.
 31. Al-Wabel MA, Tonui WK, Cui L, Martin SK, Titus RG: **Protection of susceptible BALB/c mice from challenge with *Leishmania major* by nucleoside hydrolase, a soluble exo-antigen of *Leishmania*.** *Am J Trop Med Hyg* 2007, **77**(6):1060–1065.
 32. de Matos Guedes HL, Carneiro MP, Gomes DCO, Rossi-Bergmann B, De-Simone SG: **Oligopeptidase B from *Leishmania amazonensis*: Parasitol Res** 2007, **101**(4):865–875.
 33. de Matos Guedes HL, de Carvalho RSN, Gomes DCO, Rossi-Bergmann B, De-Simone SG: **Oligopeptidase B-2 from *Leishmania amazonensis* with an unusual C-terminal extension.** *Acta Parasitol* 2008, **53**:197–204.
 34. Silva-Almeida M, Pereira BA, Ribeiro-Guimarães ML, Alves CR: **Proteinases as virulence factors in *Leishmania* spp. infection in mammals.** *Parasit Vectors* 2012, **7**(5):160.
 35. Silva-Almeida M, Souza-Silva F, Pereira BA, Ribeiro-Guimarães ML, Alves CR: **Overview of the organization of protease genes in the genome of *Leishmania* spp.** *Parasit Vectors* 2014, **7**(1):387.
 36. Zhao G, Zhou A, Lu G, Meng M, Sun M, Bai Y, Han Y, Wang L, Zhou H, Cong H, Zhao Q, Zhu XQ, He S: **Identification and characterization of *Toxoplasma gondii* aspartic protease 1 as a novel vaccine candidate against toxoplasmosis.** *Parasit Vectors* 2013, **14**(6):175.

doi:10.1186/1756-3305-7-448

Cite this article as: de Matos Guedes *et al.*: Intranasal vaccination with extracellular serine proteases of *Leishmania amazonensis* confers protective immunity to BALB/c mice against infection. *Parasites & Vectors* 2014 **7**:448.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

